Bevacizumab May Increase Risk for Motor Deficits in PreemiesBevacizumab May Increase Risk for Motor Deficits in Preemies

According to a new study in infants with ROP, intravitreal bevacizumab treatment increases the risk for motor impairment at age 18 months compared with laser treatment alone. Medscape Medical News
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Pediatrics News Source Type: news